Septerna, Inc.

Contributing Author

Recent Articles by Septerna, Inc.

Mar-01	Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy SEPN GlobeNewswire
Feb-24	Septerna to Present at TD Cowen 46th Annual Health Care Conference SEPN +10.21% GlobeNewswire
Feb-10	Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SEPN GlobeNewswire
Feb-10	Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting SEPN GlobeNewswire
Jan-08	Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer SEPN GlobeNewswire
Dec-17	Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference SEPN GlobeNewswire
Nov-25	Septerna to Participate in 8th Annual Evercore Healthcare Conference SEPN GlobeNewswire
Nov-10	Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results SEPN GlobeNewswire
Nov-03	Septerna to Participate in Upcoming Investor Conferences SEPN GlobeNewswire
Sep-29	Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors SEPN GlobeNewswire
Aug-27	Septerna to Participate in Upcoming Investor Conferences SEPN GlobeNewswire
Aug-21	Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases SEPN +5.50% GlobeNewswire
Aug-11	Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results SEPN GlobeNewswire
May-29	Septerna to Present at Jefferies Global Healthcare Conference SEPN GlobeNewswire
May-15	Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results SEPN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)